Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Jahanzaib Khwaja

Jahanzaib Khwaja

MD, FRCPath
University College London Hospitals NHS Foundation Trust
Approaching the treatment of patients with AL amyloidosis who relapse after dara-based treatment 1:50
Approaching the treatment of patients with AL amyloidosis who relapse after dara-based treatment
Jahanzaib Khwaja • 14 Jun 2025
Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis 1:48
Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
The impact of ethnicity on the risk stratification of systemic AL amyloidosis 1:53
The impact of ethnicity on the risk stratification of systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
Identification of an ultra-poor risk “Mayo Stage IIIC” subgroup in systemic AL amyloidosis 2:31
Identification of an ultra-poor risk “Mayo Stage IIIC” subgroup in systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
The limited prognostic value of dFLC in systemic AL amyloidosis 1:37
The limited prognostic value of dFLC in systemic AL amyloidosis
Jahanzaib Khwaja • 19 Oct 2024
Managing AEs associated with bortezomib in the treatment of Waldenström’s macroglobulinemia 1:14
Managing AEs associated with bortezomib in the treatment of Waldenström’s macroglobulinemia
Jahanzaib Khwaja • 19 Oct 2024
Bortezomib after BTKi failure for patients with Waldenström’s macroglobulinemia 1:32
Bortezomib after BTKi failure for patients with Waldenström’s macroglobulinemia
Jahanzaib Khwaja • 19 Oct 2024
Insights into the safety and efficacy of belantamab mafodotin in systemic AL amyloidosis 2:16
Insights into the safety and efficacy of belantamab mafodotin in systemic AL amyloidosis
Jahanzaib Khwaja • 29 May 2024
Assessing the value of various prognostic biomarkers in AL amyloidosis 2:52
Assessing the value of various prognostic biomarkers in AL amyloidosis
Jahanzaib Khwaja • 29 May 2024
The outcomes of dara-VTd in patients with treatment-naive systemic AL amyloidosis 2:06
The outcomes of dara-VTd in patients with treatment-naive systemic AL amyloidosis
Jahanzaib Khwaja • 29 May 2024
The impact of ethnicity on biomarker-based staging in AL amyloidosis 2:34
The impact of ethnicity on biomarker-based staging in AL amyloidosis
Jahanzaib Khwaja • 29 May 2024
Challenges in the diagnosis & management of Bing-Neel syndrome 1:31
Challenges in the diagnosis & management of Bing-Neel syndrome
Jahanzaib Khwaja • 10 Jun 2022
Insights into the management of Bing-Neel syndrome 1:50
Insights into the management of Bing-Neel syndrome
Jahanzaib Khwaja • 10 Jun 2022
Unmet needs in AL amyloidosis: treatment options for R/R patients 1:00
Unmet needs in AL amyloidosis: treatment options for R/R patients
Jahanzaib Khwaja • 10 Jun 2022
Belantamab mafodotin in relapsed systemic AL amyloidosis 0:48
Belantamab mafodotin in relapsed systemic AL amyloidosis
Jahanzaib Khwaja • 10 Jun 2022
The content of VJHemOnc is intended for healthcare professionals